*NOTE: Enrollment is closed for this study*
The use of cannabinoid derivatives in the treatment of a variety of neurological disorders in humans has recently been explored, particularly in the treatment of chronic pain and epilepsy. Full spectrum cannabinoid rich industrial hemp-based nutraceuticals (HBN) below 0.3% THC have been shown to have no psychotropic effects and modest activity through non-cannabinoid receptor routes affecting the serotonergic, glycinergic and GABA neurotransmission pathways that may be able to diminish pain, as well as inflammation.
Some patients will receive a placebo and regular pain medication post surgery. The other patients will get the hemp-derived nutraceutical in addition to the regular pain medication.
- Dog undergoing TPLO surgery
- Owner must sign consent form
- Owner must agree to complete canine brief inventory of pain and Helsinki scale scores for their dog
Owner is responsible for surgery and all costs associated. The study charges are covered by the Sponsor.
Garrett Davis, DVM, DACVS
Jason Tarricone, DVM, Resident in Small Animal Surgery
Red Bank Veterinary Hospital
197 Hance Ave, Tinton Falls, NJ 07724
See All Clinical Studies